HK1213583A1 - 新型α4β7肽二聚体拮抗剂 - Google Patents

新型α4β7肽二聚体拮抗剂 Download PDF

Info

Publication number
HK1213583A1
HK1213583A1 HK16101620.8A HK16101620A HK1213583A1 HK 1213583 A1 HK1213583 A1 HK 1213583A1 HK 16101620 A HK16101620 A HK 16101620A HK 1213583 A1 HK1213583 A1 HK 1213583A1
Authority
HK
Hong Kong
Prior art keywords
novel
peptide dimer
antagonists
dimer antagonists
binding
Prior art date
Application number
HK16101620.8A
Other languages
English (en)
Chinese (zh)
Inventor
Ashok Bhandari
Dinesh V. Patel
Larry C. Mattheakis
Original Assignee
Protagonist Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc. filed Critical Protagonist Therapeutics Inc.
Publication of HK1213583A1 publication Critical patent/HK1213583A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16101620.8A 2012-10-11 2013-10-11 新型α4β7肽二聚体拮抗剂 HK1213583A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261712722P 2012-10-11 2012-10-11
US201261712722P 2012-10-11
US201361807714P 2013-04-02 2013-04-02
US201361807714P 2013-04-02
US14/050,349 US9273093B2 (en) 2012-10-11 2013-10-10 α4β7 peptide dimer antagonists
US201314050349 2013-10-10
PCT/US2013/064439 WO2014059213A1 (en) 2012-10-11 2013-10-11 NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS

Publications (1)

Publication Number Publication Date
HK1213583A1 true HK1213583A1 (zh) 2016-07-08

Family

ID=50477907

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101620.8A HK1213583A1 (zh) 2012-10-11 2013-10-11 新型α4β7肽二聚体拮抗剂

Country Status (13)

Country Link
US (3) US9273093B2 (enExample)
EP (1) EP2906584B1 (enExample)
JP (2) JP6480865B2 (enExample)
KR (1) KR20150084808A (enExample)
CN (1) CN105102470A (enExample)
AU (2) AU2013329135B2 (enExample)
CA (1) CA2888479A1 (enExample)
HK (1) HK1213583A1 (enExample)
IL (1) IL238123A0 (enExample)
IN (1) IN2015DN03039A (enExample)
NZ (1) NZ706909A (enExample)
SG (2) SG11201502812WA (enExample)
WO (1) WO2014059213A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
US20140294901A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
EP3082797A4 (en) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN113621027A (zh) * 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
WO2016205488A1 (en) * 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6951825B2 (ja) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート インスリン免疫グロブリン融合タンパク質
KR20180100302A (ko) 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
US11046695B2 (en) 2015-11-11 2021-06-29 Zealand Pharma A/S Fragment synthesis of substituted cyclic peptides
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
ES2992761T3 (en) 2016-02-04 2024-12-17 Scripps Research Inst Humanized anti-cd3 antibodies, conjugates and uses thereof
EP3432906A4 (en) * 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
ES2884107T3 (es) 2016-11-11 2021-12-10 Zealand Pharma As Multímeros de péptidos cíclicos con diana en la integrina alfa-4 beta-7
WO2018205008A1 (en) * 2017-05-10 2018-11-15 Encycle Therapeutics, Inc. HOMODETIC CYCLIC PEPTIDES TARGETING α4β7 1NTEGRIN
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2020244884A1 (en) * 2019-03-28 2021-11-18 Protagonist Therapeutics, Inc. Methods for synthesizing β-homoamino acids
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
AU2021205415A1 (en) * 2020-01-10 2022-07-21 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
IL309067A (en) 2021-06-09 2024-02-01 Scripps Research Inst Long-acting dual gip/glp-1 peptide conjugates and methods of use
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) * 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
CA2106314A1 (en) * 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
AU8399998A (en) * 1997-07-11 1999-02-08 Innerdyne, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
AU750175B2 (en) 1997-11-24 2002-07-11 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US6248057B1 (en) * 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
SK14372001A3 (sk) 1999-04-12 2002-06-04 Aventis Pharma Limited Substituované bicyklické heteroarylové zlúčeniny ako antagonisty integrínu a farmaceutický prostriedok, ktorý ich obsahuje
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
AU2003301059A1 (en) 2002-12-18 2004-07-22 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
DK2332968T3 (en) 2003-11-05 2016-08-22 Dana Farber Cancer Inst Inc Alpha-helix peptides suitable for activating or inhibiting cell death
WO2005064345A2 (en) 2003-12-19 2005-07-14 Applera Corporation Methods and systems for protein and peptide evidence assembly
NZ548702A (en) 2004-01-09 2009-06-26 Pfizer Antibodies to MAdCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
JP2008504239A (ja) 2004-06-24 2008-02-14 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 複合体およびその治療的使用
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20080300180A1 (en) 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20090131317A1 (en) * 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
AU2008273814A1 (en) 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite IL-23 receptor antagonists and uses thereof
WO2009039185A1 (en) * 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
WO2009045536A2 (en) 2007-10-05 2009-04-09 The University Of North Carolina At Chapel Hill Receptor targeted oligonucleotides
DE102009007381A1 (de) * 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
US9175037B2 (en) * 2009-04-08 2015-11-03 Takeda Pharmaceutical Company Limited Neuromedin U derivative
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US9243034B2 (en) 2011-01-27 2016-01-26 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
EP2788370B1 (en) 2011-12-09 2020-02-05 The Regents of The University of California Modified mini-hepcidin peptides and methods of using thereof
US20150157692A1 (en) 2012-05-23 2015-06-11 The University Of Chicago Methods of treating obesity
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
WO2014127316A2 (en) 2013-02-15 2014-08-21 Srx Cardio, Llc Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
DK3013351T3 (da) 2013-06-24 2020-01-27 Canbas Co Ltd Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer

Also Published As

Publication number Publication date
IL238123A0 (en) 2015-05-31
CA2888479A1 (en) 2014-04-17
EP2906584A1 (en) 2015-08-19
WO2014059213A1 (en) 2014-04-17
IN2015DN03039A (enExample) 2015-10-02
EP2906584B1 (en) 2019-11-20
CN105102470A (zh) 2015-11-25
JP6480865B2 (ja) 2019-03-13
AU2018201599A1 (en) 2018-03-29
AU2013329135A1 (en) 2015-04-30
EP2906584A4 (en) 2016-06-15
JP2019001825A (ja) 2019-01-10
KR20150084808A (ko) 2015-07-22
SG10201702979SA (en) 2017-05-30
US20140193465A1 (en) 2014-07-10
SG11201502812WA (en) 2015-05-28
AU2013329135B2 (en) 2018-02-01
JP2015533833A (ja) 2015-11-26
US20160368966A1 (en) 2016-12-22
US9273093B2 (en) 2016-03-01
US20190248870A1 (en) 2019-08-15
NZ706909A (en) 2018-11-30

Similar Documents

Publication Publication Date Title
HK1213583A1 (zh) 新型α4β7肽二聚体拮抗剂
HK1221233A1 (zh) 新型α4β7肽二聚体拮抗剂
EP3960754A3 (en) Alpha4beta7 integrin thioether peptide antagonists
HK1206636A1 (zh) 用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸
MX391184B (es) ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE a4ß7 NOVEDOSOS.
MX359258B (es) Polipeptidos de enlace biparatopicos para cxcr2 y usos de los mismos.
DK3835310T3 (da) Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
WO2013138793A3 (en) Affinity reagants for protein purification
IN2015MN00139A (enExample)
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
NZ629394A (en) Synthetic brassica-derived chloroplast transit peptides
EA201600338A1 (ru) Биспецифическая связывающая молекула, связывающаяся с vegf и ang2
WO2012068406A3 (en) Use of hematopoietic growth factor mimetics
WO2009037061A3 (de) Verwendung von hydrophobin-polypeptiden als penetrationsverstärker
WO2012035050A3 (en) Factor viii variants having a decreased cellular uptake
EP2838912A4 (en) PEPTIDES FOR BINDING NUCLEOTIDE TARGETS
CL2014000459A1 (es) Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar.
WO2012136383A3 (en) Preparation of sitagliptin intermediates
PL2914612T3 (pl) Oczyszczanie polipeptydów ze stosowaniem dwuetapowej ultrafiltracji z przepływem stycznym
EA201400850A1 (ru) Альфа-амилаза
IL229722A0 (en) Dimeric binding proteins based on modified ubiquitin
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
WO2014186450A3 (en) Highly potent inhibitors of porcupine
EA033145B1 (ru) Применение полученных из pedf пептидов в стимуляции регенерации мышцы, регенерации сухожилия или артериогенеза
WO2013188432A3 (en) Asymmetric catalysts